Elocon, Mometasone Furoate

Elocon, Mometasone Furoate Newswire

Comprehensive Real-Time News Feed for Elocon, Mometasone Furoate (generic).

Results 1 - 15 of 15 in Elocon, Mometasone Furoate (generic)

  1. PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 - New Report AvailableRead the original story

    Sunday Nov 23 | PR-inside.com

    However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment.

    Comment?

  2. Now Available: PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023Read the original story

    Wednesday Nov 19 | PR-inside.com

    However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment.

    Comment?

  3. Recent Study: PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023Read the original story

    Wednesday Oct 29 | PR-inside.com

    However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment.

    Comment?

  4. Research and Markets: Merck's Dulera Asthma Treatment - Forecast and Market Analysis to 2023Read the original story

    Oct 14, 2014 | Business Wire

    Merck's Dulera is an FDC of formoterol fumarate and mometasone furoate. Mometasone furoate is a corticosteroid with potent anti-inflammatory activity.

    Comment?

  5. Recent Study: PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023Read the original story

    Oct 9, 2014 | PR-inside.com

    However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment.

    Comment?

  6. Intersect ENT Announces Publication of Positive Data From Three...Read the original story w/Photo

    Oct 8, 2014 | GlobeNewswire

    Intersect ENT, Inc. , a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced publication of positive data from three studies evaluating the company's drug eluting sinus implants. All were published in the International Forum of Allergy & Rhinology , the official journal of the American Rhinologic Society.

    Comment?

  7. Australia Asthma Treatment Drug Market Analysis and Forecast to 2023Read the original story

    Sep 27, 2014 | Emailwire.com

    A new report on 'PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023' added by RnRMarketResearch.com to its store. Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists , inhaled corticosteroids , inhaled corticosteroids and long-acting beta-agonists , and leukotriene modifiers, and has also been facing increasing generic competition.

    Comment?

  8. Intersect ENT Enrolls First Patient in Clinical Study to Expand...Read the original story w/Photo

    Sep 17, 2014 | GlobeNewswire

    Intersect ENT, Inc. , a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the enrollment of the first patient in PROGRESS, a prospective, randomized, blinded, multi-center trial to assess the safety and efficacy of the PROPEL mini steroid eluting sinus implant to treat patients with frontal sinusitis. The trial is intended to support an expanded indication for placement of PROPEL mini in the frontal sinuses, which are located behind the eyebrows.

    Comment?

  9. Study Indicates Cost Effectiveness of Intersect ENT's PROPEL Implant for Chronic SinusitisRead the original story

    Aug 11, 2014 | GlobeNewswire

    Intersect ENT, Inc. , a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced the recently-published results of a study that evaluated the economics of using the PROPEL implant versus a non-steroid eluting spacer for patients undergoing surgery for chronic sinusitis.

    Comment?

  10. Merck Announces Second-Quarter 2014 Financial ResultsRead the original story

    Jul 29, 2014 | Customer Interaction Solutions

    Merck , known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2014.

    Comment?

  11. Merck Announces Second-Quarter 2014 Financial ResultsRead the original story

    Jul 29, 2014 | Business Wire

    Non-GAAP earnings per share for the second quarter of $0.85 exclude acquisition- and divestiture-related costs, restructuring costs and certain other items.

    Comment?

  12. Court Report - July 2014 #3Read the original story

    Jul 28, 2014 | JD Supra

    GlaxoSmithKline LLC et al. v. Glenmark Generics Inc. USA 1:14-cv-00877; filed July 3, 2014 in the District Court of Delaware GlaxoSmithKline LLC et al. v.

    Comment?

  13. Elite Clinical Trials Test Doses of Dulera for AsthmaRead the original story

    Jul 19, 2014 | Menifee 24

    Elite Clinical Trials is in the works of testing different doses of Dulera in patients who have suffered from persistent asthma for more than one year.

    Comment?

  14. 33 Award Winning Medical Products: Which Medtech Companies Took Home the Gold?Read the original story w/Photo

    Jun 19, 2014 | Hispanic Business

    The winners were announced live during the 17th Annual MDEA Ceremony on . During the ceremony: The 2014 MDEA Finalists and their Suppliers were honored for their innovative contributions to the medtech industry.

    Comment?

  15. Structures and mechanism for the design of highly potent glucocorticoidsRead the original story

    Jun 2, 2014 | Cell Research

    Potency is an important aspect of this evolution as many undesirable side effects are associated with use of high-dose glucocorticoids.

    Comment?